MoonLake Immunotherapeutics recently dosed first patient in the Phase 2 clinical trial evaluating sonelokimab, for patients with moderate-to-severe hidradenitis suppurativa (HS).
https://uk.investing.com/news/stock-market-news/70-biggest-movers-from-friday-2659387
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.